Advertisement

Is Allergen Immunotherapy in Children Disease Modifying? A Review of the Evidence

  • Amanda K. Rudman Spergel
  • Michael Minnicozzi
  • Lisa M. Wheatley
  • Alkis Togias
Immunotherapy and Immunomodulators (B Vickery, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Immunotherapy and Immunomodulators

Abstract

Purpose of Review

Although evidence supports a beneficial effect of allergen immunotherapy on the symptoms of allergic respiratory disease and food allergy, it is not clear whether immunotherapy modifies the natural history of these conditions.

Recent Findings

In aeroallergen immunotherapy, studies suggest that prevention of asthma can be attained. Less evident is the ability of immunotherapy to prevent new allergen sensitizations and more studies are needed to test whether immunotherapy can continue suppressing airway symptoms after treatment discontinuation. In food allergen immunotherapy, there is evidence that unresponsiveness to a food challenge can be sustained in some treatment recipients, but little knowledge exists as to the dose and duration of treatment that can optimize this effect.

Summary

Suggestive evidence exists that allergen immunotherapy can modify allergic disease in children, but definitive studies are lacking. More research in the field is required.

Keywords

Aeroallergen immunotherapy Food allergen immunotherapy Desensitization Sustained unresponsiveness Asthma prevention 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Togias is Chief of the NIAID/DAIT Branch that has funded several of the studies cited in this review. The other authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27.  https://doi.org/10.1111/all.12268.CrossRefPubMedGoogle Scholar
  2. 2.
    Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol. 2000;105(6 Pt 2):S599–604.CrossRefPubMedGoogle Scholar
  3. 3.
    Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–57.  https://doi.org/10.1016/S0140-6736(08)61446-4.CrossRefPubMedGoogle Scholar
  4. 4.
    Rochat MK, Illi S, Ege MJ, Lau S, Keil T, Wahn U, et al. Allergic rhinitis as a predictor for wheezing onset in school-aged children. J Allergy Clin Immunol. 2010;126(6):1170–1175.e2.  https://doi.org/10.1016/j.jaci.2010.09.008.CrossRefPubMedGoogle Scholar
  5. 5.
    Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med. 2012;185(3):281–5.  https://doi.org/10.1164/rccm.201104-0660OC.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin LC, Dharmage SC, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 2015;45(1):255–64.  https://doi.org/10.1111/cea.12406.CrossRefPubMedGoogle Scholar
  7. 7.
    Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–97.  https://doi.org/10.1056/NEJMoa051378.CrossRefPubMedGoogle Scholar
  8. 8.
    Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354(19):1998–2005.  https://doi.org/10.1056/NEJMoa054692.CrossRefPubMedGoogle Scholar
  9. 9.
    Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, Is t. Secondary prevention of asthma by the use of inhaled fluticasone propionate in wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368(9537):754–62.  https://doi.org/10.1016/S0140-6736(06)69285-4.CrossRefPubMedGoogle Scholar
  10. 10.
    Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;177:1572–3.CrossRefGoogle Scholar
  11. 11.
    Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol. 2013;110(6):402–415.e9.  https://doi.org/10.1016/j.anai.2013.02.017.CrossRefPubMedGoogle Scholar
  12. 12.
    Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72(12):1825–48.  https://doi.org/10.1111/all.13208.CrossRefPubMedGoogle Scholar
  13. 13.
    Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597–631.  https://doi.org/10.1111/all.13201.CrossRefPubMedGoogle Scholar
  14. 14.
    Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99(4):450–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol. 2007;17(2):85–91.PubMedGoogle Scholar
  16. 16.
    Lim JH, Kim JY, Han DH, Lee CH, Hong SN, Wee JH, et al. Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. PLoS One. 2017;12(8):e0182295.  https://doi.org/10.1371/journal.pone.0182295.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72(5):691–704.  https://doi.org/10.1111/all.13104.CrossRefPubMedGoogle Scholar
  18. 18.
    Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2000;162(6):2048–52.  https://doi.org/10.1164/ajrccm.162.6.9909087.CrossRefPubMedGoogle Scholar
  19. 19.
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855–9.  https://doi.org/10.1111/j.1398-9995.2006.01068.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8.  https://doi.org/10.1111/j.1398-9995.2007.01451.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7.  https://doi.org/10.1016/j.jaci.2004.07.012.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–38 e13.  https://doi.org/10.1016/j.jaci.2017.06.014. Children randomized to grass SLIT or placebo for 3 years and followed for 2-years after the completion of therapy. Starting in year 2 and through the final 5 th year, SLIT-treated participants were significantly less likely to be using asthma medications or experiencing asthma symptoms than those who received Placebo. CrossRefPubMedGoogle Scholar
  24. 24.
    Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the third national health and nutrition examination survey. J Allergy Clin Immunol. 2007;120(5):1139–45.  https://doi.org/10.1016/j.jaci.2007.07.056.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Simpson A, Soderstrom L, Ahlstedt S, Murray CS, Woodcock A, Custovic A. IgE antibody quantification and the probability of wheeze in preschool children. J Allergy Clin Immunol. 2005;116(4):744–9.  https://doi.org/10.1016/j.jaci.2005.06.032.CrossRefPubMedGoogle Scholar
  26. 26.
    Lau S, Illi S, Sommerfeld C, Niggemann B, Bergmann R, von Mutius E, et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group Lancet. 2000;356(9239):1392–7.Google Scholar
  27. 27.
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–75.  https://doi.org/10.1056/NEJM199908123410702.CrossRefPubMedGoogle Scholar
  28. 28.
    Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–725.e5.  https://doi.org/10.1016/j.jaci.2011.12.973.CrossRefPubMedGoogle Scholar
  29. 29.
    • Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317(6):615–25.  https://doi.org/10.1001/jama.2016.21040. This trial demonstrated that 3 years of AIT with either SLIT or SCIT was insufficent to produce tolerance one year after discontinuation of therapy. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002;57(4):306–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of aeroallergen immunotherapy. Subcutaneous Immunotherapy and Sublingual Immunotherapy Immunol Allergy Clin North Am. 2016;36(1):71–86.  https://doi.org/10.1016/j.iac.2015.08.003.CrossRefPubMedGoogle Scholar
  32. 32.
    Wambre E, DeLong JH, James EA, Torres-Chinn N, Pfutzner W, Mobs C, et al. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. J Allergy Clin Immunol. 2014;133(3):872–879.e7.  https://doi.org/10.1016/j.jaci.2013.10.054.CrossRefPubMedGoogle Scholar
  33. 33.
    Renand A, Shamji MH, Harris KM, Qin T, Wambre E, Scadding GW, et al. Synchronous immune alterations mirror clinical response during allergen immunotherapy. J Allergy Clin Immunol. 2018;141(5):1750–1760.e1.  https://doi.org/10.1016/j.jaci.2017.09.041.CrossRefPubMedGoogle Scholar
  34. 34.
    Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172(5):3252–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin a and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40(4):598–606.  https://doi.org/10.1111/j.1365-2222.2010.03462.x.PubMedCrossRefGoogle Scholar
  36. 36.
    Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol. 2007;178(7):4658–66.CrossRefPubMedGoogle Scholar
  37. 37.
    van de Veen W, Stanic B, Wirz OF, Jansen K, Globinska A, Akdis M. Role of regulatory B cells in immune tolerance to allergens and beyond. J Allergy Clin Immunol. 2016;138(3):654–65.  https://doi.org/10.1016/j.jaci.2016.07.006.CrossRefPubMedGoogle Scholar
  38. 38.
    Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt 1):744–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43.  https://doi.org/10.1056/NEJMoa1200435.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304.  https://doi.org/10.1016/S0140-6736(13)62301-6.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–485.e3.  https://doi.org/10.1016/j.jaip.2017.09.016.CrossRefPubMedGoogle Scholar
  42. 42.
    Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60.  https://doi.org/10.1016/j.jaci.2008.09.030.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–1282.e6.  https://doi.org/10.1016/j.jaci.2014.11.005.CrossRefPubMedGoogle Scholar
  44. 44.
    Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809.  https://doi.org/10.1001/jama.2017.16591.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–1252.e9.  https://doi.org/10.1016/j.jaci.2016.08.017.CrossRefPubMedGoogle Scholar
  46. 46.
    Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85–94.  https://doi.org/10.1016/S2468-1253(17)30392-8.CrossRefPubMedGoogle Scholar
  47. 47.
    •• Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, et al. Effect of avoidance on peanut allergy after early peanut consumption. N Engl J Med. 2016;374(15):1435–43.  https://doi.org/10.1056/NEJMoa1514209. Follow -on study to the LEAP trial where participants who had been consuming peanuts avoided them between 5 and 6 years of age and maintained their ability to eat them without reaction. CrossRefPubMedGoogle Scholar
  48. 48.
    • Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117–1127.e10.  https://doi.org/10.1016/j.jaci.2015.12.1316. This study suggests that, as with AIT, that a longer duration of FAIT may be more effective for development of sustained unresponsivenss. CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–181.e8.  https://doi.org/10.1016/j.jaci.2016.05.027.CrossRefPubMedGoogle Scholar
  50. 50.
    •• Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13.  https://doi.org/10.1056/NEJMoa1414850. Landmark study demonstrating that in children at high risk of food allergy due to eczema or egg allergy, early consumption of peanut prevents the develoment of peanut allergy. CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Wright BL, Kulis M, Orgel KA, Burks AW, Dawson P, Henning AK, et al. Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness. Allergy. 2016;71(11):1552–60.  https://doi.org/10.1111/all.12895.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10.  https://doi.org/10.1016/j.jaci.2013.12.1037.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83–91.e1.  https://doi.org/10.1016/j.jaci.2010.04.030.CrossRefPubMedGoogle Scholar
  54. 54.
    Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9(401):eaam9171.  https://doi.org/10.1126/scitranslmed.aam9171.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–744.e8.  https://doi.org/10.1016/j.jaci.2014.11.034.CrossRefPubMedGoogle Scholar
  56. 56.
    Hsiao K-H, Ponsonby A-L, Axelrad C, Pitkin S, Tang MLK. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child & Adolescent Health, 2017;1(2):97–105.  https://doi.org/10.1016/S2352-4642(17)30041-X.
  57. 57.
    Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75.  https://doi.org/10.1016/j.jaci.2013.11.007.CrossRefPubMedGoogle Scholar
  58. 58.
    Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105(6):444–50.  https://doi.org/10.1016/j.anai.2010.09.030.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Escudero C, Rodriguez Del Rio P, Sanchez-Garcia S, Perez-Rangel I, Perez-Farinos N, Garcia-Fernandez C, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–43.  https://doi.org/10.1111/cea.12604.CrossRefPubMedGoogle Scholar
  60. 60.
    Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–1110.e11.  https://doi.org/10.1016/j.jaci.2015.10.005.CrossRefPubMedGoogle Scholar
  61. 61.
    Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–455.e5.  https://doi.org/10.1016/j.jaci.2011.10.023.CrossRefPubMedGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright may apply 2018

Authors and Affiliations

  • Amanda K. Rudman Spergel
    • 1
  • Michael Minnicozzi
    • 1
  • Lisa M. Wheatley
    • 1
  • Alkis Togias
    • 1
  1. 1.Division of Allergy, Immunology and Transplantation, Allergy, Asthma and Airway Biology BranchNational Institute of Allergy and Infectious Diseases, NIHRockvilleUSA

Personalised recommendations